Mode
Text Size
Log in / Sign up

cGAS-STING pathway serves as a central axis for innate immune activation in MASLD and HCCNew research identifies a key immune pathway in fatty liver disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize the cGAS-STING pathway as a central axis for innate immune activation in MASLD and HCC progression.

This systematic review examines the cGAS-STING pathway as a central axis of cytosolic DNA sensing and innate immune activation in the context of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and hepatocellular carcinoma (HCC).

The authors synthesize evidence indicating that the cGAS-STING pathway regulates several key pathological processes, including lipid metabolism imbalance, hepatic inflammation amplification, hepatic stellate cell (HSC) activation, and malignant transformation. These processes are critical drivers in the progression from simple steatosis to advanced fibrosis and malignancy.

Regarding therapeutic potential, the review notes that natural compounds, traditional Chinese medicine, and nanosystems targeting the cGAS-STING pathway have demonstrated promising effects. However, the review does not provide specific clinical trial data or quantified effect sizes for these interventions. The findings offer a theoretical foundation for elucidating disease mechanisms and developing diagnostic and therapeutic strategies, though clinical evidence remains limited.

How this fits prior evidence

This systematic review addresses a gap in the mechanistic understanding of MASLD and HCC by identifying the cGAS-STING pathway as a central axis for innate immune activation. While prior coverage identified the role of hepatocyte senescence and SASP signaling in fibrotic remodeling, this review adds a different immunological mechanism. It also provides a theoretical basis for treating conditions related to the 15 germline loci associated with hepatocellular carcinoma and the progression of liver fibrosis.

Living with fatty liver disease often involves a complex chain of events. It starts with fat buildup and can lead to inflammation, scarring, and even liver cancer. Researchers are looking closely at a specific immune pathway called cGAS-STING to understand how these problems develop.

This pathway acts as a central hub for sensing DNA and activating the body's innate immune system. The review found that this pathway influences several key issues, including how the liver handles fats, the level of inflammation, and the activation of cells that cause scarring. It may also play a role in the transformation of cells into cancer.

While the research is still in the early stages of establishing a foundation, it highlights potential paths for future treatment. Some natural compounds, traditional Chinese medicine, and specialized delivery systems targeting this pathway have shown promise. Because this research provides a theoretical foundation, it helps scientists develop better ways to diagnose and treat liver disease.

What this means for you:
The cGAS-STING pathway is a central hub for immune responses and may offer a target for treating liver disease.

Common questions

What is the cGAS-STING pathway?

The cGAS-STING pathway is a central axis for sensing cytosolic DNA and activating the innate immune system. In the context of liver disease, it helps regulate how the body responds to inflammation and manages the balance of lipids in the liver.

How does this pathway affect liver health?

This pathway impacts several key areas of liver health. It regulates lipid metabolism imbalance, the amplification of liver inflammation, the activation of cells that cause scarring, and the potential for cells to turn into cancer.

Are there any treatments that target this pathway?

Research shows that natural compounds, traditional Chinese medicine, and nanosystems targeting the cGAS-STING pathway have shown promising effects. However, these findings are currently a theoretical foundation for future treatment strategies.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic metabolic liver disease worldwide, encompassing a spectrum that includes simple steatosis, metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and hepatocellular carcinoma (HCC), with immune-metabolic-inflammatory dysregulation at its core pathogenesis. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway serves as the central axis of cytosolic DNA sensing and innate immune activation. Endogenous stimuli, including mitochondrial DNA leakage, DNA damage, and gut microbial DNA translocation, can persistently activate this pathway, which in turn regulates lipid metabolism imbalance, hepatic inflammation amplification, hepatic stellate cell (HSC) activation, and malignant transformation through downstream signaling axes, driving the full spectrum of MASLD pathology. Molecules associated with the cGAS-STING pathway may serve as non-invasive diagnostic biomarkers for MASLD, and natural compounds, traditional Chinese medicine, and nanosystems targeting this pathway have demonstrated promising therapeutic effects. This review systematically summarizes the molecular mechanisms of the cGAS-STING pathway, its regulatory roles in MASLD, and advances in targeted therapy, providing a theoretical foundation for disease mechanism elucidation and the development of diagnostic and therapeutic strategies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.